BCL2A1 and Miyoshi myopathy: If BFL-1 expression is indeed a significant mediator of NFκB-induced therapy resistance in MM, (in)direct inhibition of BFL-1 could have therapeutic potential for treatment of RR-MM patients, especially since direct and selective targeting of NFκB signaling upstream of BFL-1 has been proven challenging.